Biotech entity
GLP-1 Receptor Agonists is most often covered alongside Novo Nordisk, which appears in 2 of these 2 stories. Across a 153-day span, the pace is roughly 0.1 stories per week. Source depth averages 5 original sources per story, versus 3.8 across the same-window beat baseline.
Last mentioned: Jul 21, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
GLP-1 Receptor Agonists is most often covered alongside Novo Nordisk, which appears in 2 of these 2 stories. Across a 153-day span, the pace is roughly 0.1 stories per week. Source depth averages 5 original sources per story, versus 3.8 across the same-window beat baseline. Their average consequence score of 6 runs below the beat's 6.2 for that window. The clearest coverage concentration is clinical-trial: 1 of 2 stories, with the rest divided among 1 other category. This profile follows 2 Biotech stories mentioning GLP-1 Receptor Agonists across the period from February 19, 2026 to July 21, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 575 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GLP-1 Receptor Agonists. Shared-story counts are live from our verified record — not editorial picks.
Lawsuit Filed
Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act.
FDA Approves Wegovy 7.2 mg
Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss.
The litigation underscores the GLP-1 dosing race: Wegovy 7.2 mg’s clinical superiority reshapes head-to-head comparisons, forcing Lilly to legally defend its ad strategy amid rapid innovation.
As GLP-1 receptor agonists like semaglutide and tirzepatide dominate the obesity market, the focus is shifting toward integrated nutritional strategies to mitigate muscle loss and gastrointestinal side effects. This evolution marks a transition from simple weight reduction to comprehensive body composition management.
GLP-1 Receptor Agonists is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
